Skip to main content

Table 2 Preoperative and postoperative outcome parameters and schedule of study visits and follow-up

From: A safety study of transumbilical single incision versus conventional laparoscopic surgery for colorectal cancer: study protocol for a randomized controlled trial

Measures

Preoperative

Daily in-hospital study visits

Follow-up

POD 0b

POD 1

POD 2

POD 3

POD 4

POD 5

POD ≥6

M1

M3

M6

M9

M12

M15

M18

M21

M24

M30

M36

M42

M48

M54

M60

Inflammatory parameters (WBC, NE %, CRP, IL-6, TNF-α)

Xa

Xc

Xc

  

Xc

                 

VAS score

  

X

X

X

 

X

                

Short-term recoveryd

  

X

X

X

X

X

X

               

Post-voiding residual urine

Xa

   

X

                  

EORTC QLQ-C30

Xa

       

X

X

X

            

EORTC QLQ-CR29

Xa

       

X

X

X

            

IPSS

Xa

       

X

X

X

            

BIQ

        

X

X

X

            

Abdominal incision photograph

 

X

      

X

X

X

            

Physical examination

Xa

       

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

CEA, CA72-4, CA19-9

X

        

X

X

X

X

X

X

X

X

X

X

X

X

X

X

Chest radiography

X

        

X

X

X

X

X

X

X

X

X

X

X

X

X

X

Liver ultrasonography

         

X

 

X

 

X

 

X

 

X

 

X

 

X

 

Abdominal and pelvic CT scan

X

         

X

 

X

 

X

 

X

 

X

 

X

 

X

Colonoscopy or EUS

X

         

X

 

X

 

X

 

X

 

X

 

X

 

X

Adverse event

 

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

  1. aPreoperative study visits will be scheduled within 7 days before surgery; bThe study visit on POD 0 will be scheduled during and after surgery; cInflammatory parameters will be measured at postoperative 4 hours, 24 hours, and 96 hours after skin suture; dShort-term recovery, including time to first flatus, time to resuming liquid diet and soft diet, time to ambulating independently and discharge. POD, postoperative day; M, month; WBC, white blood cells; NE %, neutrophil percentage; CRP, C-reactive protein; IL-6, interleukin-6; TNF-α, tumor necrosis factor-α; VAS, visual analogue scale; QLQ-C30, Quality of Life Questionnaire-Core 30; QLQ-CR29, Quality of Life Questionnaire-Colorectal 29; IPSS, International Prostatic Symptom Score; BIQ, Body Image Questionnaire; CEA, carcinoembryonic antigen; CA 72-4, carbohydrate antigen 72-4; CA 19-9, carbohydrate antigen 19-9; CT, computed tomography; EUS, endoscopic ultrasonography